BREAKING NEWS. Entering into the specialty Devices business. Our Pharmacy Services For All Your Specialty Drugs & Devices need. If you have requirement of specialty medicines/device. do not look beyond VHSPL. images : source fiercepharma.
1. Xbrane Biopharma Announces Product Portfolio Update With A New Full Strategic Focus On Biosimilars 2. Celltrion Finalizes Clinical Trials For Subcutaneous Remsima
Pioneer in the India Health Care Supply Chain Segment to become the most Advanced, Accurate, Transparent & Compliant Pharma Service Provider, with its Cutting Edge IOT Based Technology Platform – VHS LogiX. A Real Time Data Managed Service Offering Platform. An IOT Enabled Supply Chain Management Technology Platform called VHS LogiX is built & …
Billion $ info… Worldwide drug in clinical trials YES Indication. YES Phase wise. YES Conducted by YES Contact no & mail id with the address of trial done by YES Sponsor. YES Molecule launching year ???? Contact us. courtesy centrewatch
While biosimilars’ growth potential appears bright, winning with biosimilars in emerging markets is not a simple undertaking.
Companies seeking entry or expansion should craft a strategy to address the specific challenges in the emerging markets by choosing the right partner.
• Today, ensuring Cold Chain Products are continuously stored, handled and transported under adequate environmental conditions (temperature) is crucial. • Automated Monitoring Systems now enable to monitor and track storage and transport conditions throughout the Supply Chain up to the end-users.
Latest news sub : Biologics FDA chief says pharmas use rebates to block biosimilar competition Gottlieb: If Americans could have bought FDA-approved biosimilars last year, they could have saved more than $4.5 billion.
Rheumatology and Oncology Providers Voice Concern Over CMS Step Therapy Plan.
Big Pharma vs Big Pharma in court battles over biosimilar drugs Reuters - The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals' complex biological medicines.
Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab
I. Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab Results based on retrospective analysis of two large randomised trials. Date: 17 Aug 2018 II. Eisai, Merck take on Bayer's Nexavar with new liver cancer nod for Lenvima. Aug 17, 2018 10:15 am